Lets Make 2016 the Takeoff Year for Publishing in the Drug Repurposing Field

After a holiday season that – hopefully! – all of you have enjoyed, it is now time to refocus on the task at hand: advancing drug development by delving into the universe of known drugs, drug candidates, and discontinued investigational compounds, to discover new therapeutic opportunities.

Achieving leadership in drug repurposing and repositioning is rapidly becoming a matter of applying a bundle of advanced technologies to sift through the huge pool of available molecules and data that our exploratory drive has yet to touch. The methods and approaches are hugely diverse – from cheminformatics to high-throughput screening to data and text mining, to name just a few. A scientific publishing platform that offers an integrated perspective already exists in the form of the twice-yearly Special Issues of the well-established peer review journal, ASSAY and Drug Development Technologies. The December 2015 issue is a first-rate example how the most diverse approaches can combine to achieve the goal.

We are now calling for submission of manuscripts to be published in the mid-2016 issue. Mary Ann Liebert, Inc.’s ASSAY has been around for a decade, it is listed in Medline and in all key indexing services with an Impact Factor of 1.529, and it offers an Open Access option; all of which combines to guarantee broad readership of your research results. The more high-quality contributions we get, the easier it will be to expand this unique platform.

This Call for Manuscripts also goes out as a Group Announcement to all 751 current members of our LinkedIn platform, “Drug repurposing – reprofiling – repositioning.” Join the discussion and informal exchange there to follow cutting-edge events in the field.